Expression of the PTTG1 oncogene is associated with aggressive clear cell renal cell carcinoma

Bill Wondergem, Zhongfa Zhang, Dachuan Huang, Choon Kiat Ong, Julie Koeman, David Van t Hof, David Petillo, Aikseng Ooi, John Anema, Brian Lane, Richard J. Kahnoski, Kyle A. Furge, Bin Tean Teh

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

The pituitary tumor transforming gene (PTTG1) is a recently discovered oncogene implicated in malignant progression of both endocrine and nonendocrine malignancies. Clear cell renal cell carcinoma (ccRCC) is cytogenetically characterized by chromosome 3p deletions that harbor the ccRCC-related von Hippel-Lindau, PBRM1, BAP1, and SETD2 tumor suppressor genes, along with chromosome 5q amplifications where the significance has been unclear. PTTG1 localizes to the chromosome 5q region where amplifications occur in ccRCC. In this study, we report a functional role for PTTG1 in ccRCC tumorigenesis. PTTG1 was amplified in ccRCC, overexpressed in tumor tissue, and associated with high-grade tumor cells and poor patient prognosis. In preclinical models, PTTG1 ablation reduced tumorigenesis and invasion. An analysis of gene expression affected by PTTG1 indicated an association with invasive and metastatic disease. PTTG1-dependent expression of the RhoGEF proto-oncogene ECT2 was observed in a number of ccRCC cell lines. Moreover, ECT2 expression correlated with PTTG1 expression and poor clinical features. Together, our findings reveal features of PTTG1 that are consistent with its identification of an oncogene amplified on chromsome 5q in ccRCC, where it may offer a novel therapeutic target of pathologic significance in this disease.

Original languageEnglish (US)
Pages (from-to)4361-4371
Number of pages11
JournalCancer Research
Volume72
Issue number17
DOIs
StatePublished - Sep 1 2012
Externally publishedYes

Fingerprint

Oncogenes
Renal Cell Carcinoma
Carcinogenesis
Chromosomes
Rho Guanine Nucleotide Exchange Factors
Neoplasms
Chromosome Deletion
Proto-Oncogenes
Pituitary Neoplasms
Tumor Suppressor Genes
Gene Expression
Cell Line

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Wondergem, B., Zhang, Z., Huang, D., Ong, C. K., Koeman, J., Hof, D. V. T., ... Teh, B. T. (2012). Expression of the PTTG1 oncogene is associated with aggressive clear cell renal cell carcinoma. Cancer Research, 72(17), 4361-4371. https://doi.org/10.1158/0008-5472.CAN-11-2330

Expression of the PTTG1 oncogene is associated with aggressive clear cell renal cell carcinoma. / Wondergem, Bill; Zhang, Zhongfa; Huang, Dachuan; Ong, Choon Kiat; Koeman, Julie; Hof, David Van t; Petillo, David; Ooi, Aikseng; Anema, John; Lane, Brian; Kahnoski, Richard J.; Furge, Kyle A.; Teh, Bin Tean.

In: Cancer Research, Vol. 72, No. 17, 01.09.2012, p. 4361-4371.

Research output: Contribution to journalArticle

Wondergem, B, Zhang, Z, Huang, D, Ong, CK, Koeman, J, Hof, DVT, Petillo, D, Ooi, A, Anema, J, Lane, B, Kahnoski, RJ, Furge, KA & Teh, BT 2012, 'Expression of the PTTG1 oncogene is associated with aggressive clear cell renal cell carcinoma', Cancer Research, vol. 72, no. 17, pp. 4361-4371. https://doi.org/10.1158/0008-5472.CAN-11-2330
Wondergem, Bill ; Zhang, Zhongfa ; Huang, Dachuan ; Ong, Choon Kiat ; Koeman, Julie ; Hof, David Van t ; Petillo, David ; Ooi, Aikseng ; Anema, John ; Lane, Brian ; Kahnoski, Richard J. ; Furge, Kyle A. ; Teh, Bin Tean. / Expression of the PTTG1 oncogene is associated with aggressive clear cell renal cell carcinoma. In: Cancer Research. 2012 ; Vol. 72, No. 17. pp. 4361-4371.
@article{c80c6884a5f14d0aa2205dedd3e1a148,
title = "Expression of the PTTG1 oncogene is associated with aggressive clear cell renal cell carcinoma",
abstract = "The pituitary tumor transforming gene (PTTG1) is a recently discovered oncogene implicated in malignant progression of both endocrine and nonendocrine malignancies. Clear cell renal cell carcinoma (ccRCC) is cytogenetically characterized by chromosome 3p deletions that harbor the ccRCC-related von Hippel-Lindau, PBRM1, BAP1, and SETD2 tumor suppressor genes, along with chromosome 5q amplifications where the significance has been unclear. PTTG1 localizes to the chromosome 5q region where amplifications occur in ccRCC. In this study, we report a functional role for PTTG1 in ccRCC tumorigenesis. PTTG1 was amplified in ccRCC, overexpressed in tumor tissue, and associated with high-grade tumor cells and poor patient prognosis. In preclinical models, PTTG1 ablation reduced tumorigenesis and invasion. An analysis of gene expression affected by PTTG1 indicated an association with invasive and metastatic disease. PTTG1-dependent expression of the RhoGEF proto-oncogene ECT2 was observed in a number of ccRCC cell lines. Moreover, ECT2 expression correlated with PTTG1 expression and poor clinical features. Together, our findings reveal features of PTTG1 that are consistent with its identification of an oncogene amplified on chromsome 5q in ccRCC, where it may offer a novel therapeutic target of pathologic significance in this disease.",
author = "Bill Wondergem and Zhongfa Zhang and Dachuan Huang and Ong, {Choon Kiat} and Julie Koeman and Hof, {David Van t} and David Petillo and Aikseng Ooi and John Anema and Brian Lane and Kahnoski, {Richard J.} and Furge, {Kyle A.} and Teh, {Bin Tean}",
year = "2012",
month = "9",
day = "1",
doi = "10.1158/0008-5472.CAN-11-2330",
language = "English (US)",
volume = "72",
pages = "4361--4371",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "17",

}

TY - JOUR

T1 - Expression of the PTTG1 oncogene is associated with aggressive clear cell renal cell carcinoma

AU - Wondergem, Bill

AU - Zhang, Zhongfa

AU - Huang, Dachuan

AU - Ong, Choon Kiat

AU - Koeman, Julie

AU - Hof, David Van t

AU - Petillo, David

AU - Ooi, Aikseng

AU - Anema, John

AU - Lane, Brian

AU - Kahnoski, Richard J.

AU - Furge, Kyle A.

AU - Teh, Bin Tean

PY - 2012/9/1

Y1 - 2012/9/1

N2 - The pituitary tumor transforming gene (PTTG1) is a recently discovered oncogene implicated in malignant progression of both endocrine and nonendocrine malignancies. Clear cell renal cell carcinoma (ccRCC) is cytogenetically characterized by chromosome 3p deletions that harbor the ccRCC-related von Hippel-Lindau, PBRM1, BAP1, and SETD2 tumor suppressor genes, along with chromosome 5q amplifications where the significance has been unclear. PTTG1 localizes to the chromosome 5q region where amplifications occur in ccRCC. In this study, we report a functional role for PTTG1 in ccRCC tumorigenesis. PTTG1 was amplified in ccRCC, overexpressed in tumor tissue, and associated with high-grade tumor cells and poor patient prognosis. In preclinical models, PTTG1 ablation reduced tumorigenesis and invasion. An analysis of gene expression affected by PTTG1 indicated an association with invasive and metastatic disease. PTTG1-dependent expression of the RhoGEF proto-oncogene ECT2 was observed in a number of ccRCC cell lines. Moreover, ECT2 expression correlated with PTTG1 expression and poor clinical features. Together, our findings reveal features of PTTG1 that are consistent with its identification of an oncogene amplified on chromsome 5q in ccRCC, where it may offer a novel therapeutic target of pathologic significance in this disease.

AB - The pituitary tumor transforming gene (PTTG1) is a recently discovered oncogene implicated in malignant progression of both endocrine and nonendocrine malignancies. Clear cell renal cell carcinoma (ccRCC) is cytogenetically characterized by chromosome 3p deletions that harbor the ccRCC-related von Hippel-Lindau, PBRM1, BAP1, and SETD2 tumor suppressor genes, along with chromosome 5q amplifications where the significance has been unclear. PTTG1 localizes to the chromosome 5q region where amplifications occur in ccRCC. In this study, we report a functional role for PTTG1 in ccRCC tumorigenesis. PTTG1 was amplified in ccRCC, overexpressed in tumor tissue, and associated with high-grade tumor cells and poor patient prognosis. In preclinical models, PTTG1 ablation reduced tumorigenesis and invasion. An analysis of gene expression affected by PTTG1 indicated an association with invasive and metastatic disease. PTTG1-dependent expression of the RhoGEF proto-oncogene ECT2 was observed in a number of ccRCC cell lines. Moreover, ECT2 expression correlated with PTTG1 expression and poor clinical features. Together, our findings reveal features of PTTG1 that are consistent with its identification of an oncogene amplified on chromsome 5q in ccRCC, where it may offer a novel therapeutic target of pathologic significance in this disease.

UR - http://www.scopus.com/inward/record.url?scp=84865762066&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84865762066&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-11-2330

DO - 10.1158/0008-5472.CAN-11-2330

M3 - Article

C2 - 22805307

AN - SCOPUS:84865762066

VL - 72

SP - 4361

EP - 4371

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 17

ER -